KLOW: What a Four-Component "GLOW-Plus-KPV" Blend Actually Is — and Why the Certificate Has to Identify Each Peptide

Research use only: the materials discussed here are sold for laboratory research. They are not approved drugs or supplements and are not for human or veterinary use.

Research context: this overview summarises published laboratory literature for researchers. It contains no guidance on human use, dosing or preparation for administration.

Disclosure: this overview was prepared on behalf of Peptide Titans, a research-peptide supplier, and links to its product page.

Short answer: "KLOW" is a retail name for a multi-peptide blend, not a single molecule. On the listing discussed here, it is a co-lyophilised 80 mg vial described as GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. That is the three-component combination often sold as "GLOW," plus the tripeptide KPV. There is a substantial literature on some of the components individually, and almost none on this four-component mixture. A methods section should name each peptide, the nominal amounts, and the lot. The name alone does not specify a chemical entity, and nothing in this overview is a basis for human use.

What the name refers to on this listing

Blend formulas vary between suppliers, and the same name can hide different ratios. The first research question is therefore simple: what is in this specific vial?

As one example, peptidetitans.com describes KLOW as a multi-peptide research blend containing GHK-Cu (50 mg), BPC-157 (10 mg), TB-500 (10 mg) and KPV (10 mg), supplied as a co-lyophilised powder in a single 80 mg vial, with a lot-specific certificate of analysis. The short description states that blend composition and ratios may vary by formulation, and that the material is intended for research use only, not for human or veterinary use. The listing classifies the product as a multi-peptide blend rather than a single sequence, records the formula and molecular weight as variable, and describes the appearance as a blue-tinted to off-white lyophilised powder, a colour that is consistent with the presence of a copper-peptide complex.

Relative to a typical three-component "GLOW" vial, the distinguishing feature is the fourth peptide, KPV, and the total labelled mass of 80 mg rather than 70 mg, with the same 50/10/10 pattern for GHK-Cu, BPC-157 and TB-500 in the example above. Those numbers are nominal. They should be checked against the lot certificate, not assumed from the name.

Three practical points follow:

The components, briefly, without treating the blend as a new molecule

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. It has a long cell-culture literature of its own and is not re-reviewed here. In this vial it is the major labelled component.

BPC-157 is a 15-amino-acid synthetic peptide. Almost all of its published record is preclinical. That record should be read at the level of the individual peptide. It does not describe a four-component blend.

KPV is the tripeptide Lys-Pro-Val. It likewise has its own, mostly preclinical, literature. Adding it to a vial does not automatically transfer any finding about KPV, or about a three-component blend, to the mixture.

TB-500 is the component where the label matters most. Full-length thymosin beta-4 is a naturally occurring 43-residue peptide. In 2012, Esposito, Deventer, Goeman, Van der Eycken and Van Eenoo reported in Drug Testing and Analysis (PMID 22962027; doi 10.1002/dta.1402) a chemical characterisation of a product marketed as TB-500. Using high-resolution LC-MS, they identified the N-terminally acetylated 17–23 fragment of thymosin beta-4, Ac-LKKTETQ. That is a seven-residue peptide, not the 43-residue protein. Supplier descriptions of TB-500 vary; some list it as a 43-amino-acid thymosin beta-4 analog. The name alone cannot settle which species is present. A seven-residue fragment and a 43-residue peptide have very different masses, so the mass-spectrometry result on the certificate is the way to see which species was actually measured in that lot. Literature on full-length thymosin beta-4 should not be cited as evidence for a fragment, or the reverse.

What has been published on the combination

We did not treat the blend as if it had a dedicated experimental literature. A ClinicalTrials.gov search for "KLOW" on 12 November 2026 returned a single record, an educational study in cystic fibrosis whose abstract uses the typographical string "klow" for "low"; it is not a study of this peptide blend. We found no registered interventional study of a GHK-Cu, BPC-157, TB-500 and KPV combination under that name.

The practical implication is the same one that applies to other named blends. Anyone working with the mixture is extrapolating from single-compound papers, unless they run the combination as an experiment with appropriate controls. "More components" is not evidence of additive effects. Copper ions can coordinate with peptides, and the four constituents have different stabilities and chromatographic behaviours. Without single-component arms, a result cannot be attributed to the blend as such.

What a laboratory protocol actually needs

A useful certificate for a blend should report an identity result for each peptide, not one "blend" mass. It should also say how purity was calculated when several main peaks are present, and it should state how the copper complex was characterised. The lot number on the vial should match the certificate. Results from one lot should not be generalised to another, and the listing's own note that ratios may vary should be taken at face value.

General peptide-handling guidance applies. Bachem's published handling notes observe that peptides tend to be hygroscopic, and they recommend allowing a sealed container to reach ambient temperature in a dry atmosphere before opening, then weighing quickly and resealing. They also recommend aliquoting solutions and keeping them frozen, and they advise against long-term storage in solution. The Peptide Titans listing specifies −20 °C to −80 °C for long-term storage of the sealed lyophilised vial, protected from light and moisture.

Bottom line

KLOW, on this listing, is an 80 mg co-lyophilised blend of four named peptides in a 50/10/10/10 nominal ratio, with KPV as the component that distinguishes it from a three-component GLOW-type vial. The components can be specified. The combination, as a combination, is largely unstudied. If you work with it, name each peptide, verify each by mass, record the lot, and keep the interpretation inside the experiment you actually ran. Nothing in this overview is a basis for human use.

Research use only: products discussed in this article are sold strictly for laboratory research. They are not for human or veterinary use and are not intended to diagnose, treat, cure, or prevent any disease. Product details were read from the supplier's listing as captured in October–November 2026 (Ahrefs Site Audit crawl of 11 November 2026, which recorded the product URL as HTTP 200, indexable and self-canonical, together with the store catalog record of 23 October 2026 for composition and vial size). Details may change.

Sources